1.88 USD
↘ 0.16 (7.84%)AT CLOSE (11:59 AM EDT)
Allogene Therapeutics, Inc. Common Stock
ALLONASDAQ • USD
1.90
↗ 0.02 (1.12%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
1.90
↗ 0.02 (1.12%)
Market: CLOSED
Open?$2.01
High?$2.03
Low?$1.87
Prev. Close?$2.04
Volume?8.0M
Avg. Volume?6.8M
VWAP?$1.92
Rel. Volume?1.18x
Bid / Ask
Bid?$1.62 × 100
Ask?$2.18 × 100
Spread?$0.56
Midpoint?$1.90
Valuation & Ratios
Market Cap?648.9M
Shares Out?345.2M
Float?170.0M
Float %?69.4%
P/E Ratio?N/A
P/B Ratio?2.33
EPS?-$0.50
Dividend?0.00%
Ex-Dividend?N/A
Allogene Therapeutics, Inc. Common Stock (ALLO) trades at $1.88 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics suggest ALLO is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Themes
Employees
152
Market Cap
648.9M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2018-10-11
Address
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 457-2700
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 457-2700
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?77
Short Sent.?20
Piotroski F-Score?0/9Weak
Altman Z-Score?-4.78Distress
Confidence?46%Low
Short InterestSqueeze Risk
Short % of Float?24.87%Squeeze Risk
Short Interest?42.3M
Days to Cover?6.4
Free Float170.0M
Avg Daily Volume6.6M
Settlement Date2026-05-15
Financial Health
Current Ratio?9.65Strong
Quick Ratio?9.65Strong
Cash Ratio?1.07Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?2.33CHEAP▾
Peers100
S&P67
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-3.5CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-62.3%WEAK▾
S&P3
ROA?-43.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-109526000
Enterprise Value?$618.6M
Fundamentals ratios updated end of day